Loading organizations...
Visionary Ventures is a specialized venture capital fund, exclusively investing in life sciences, particularly ophthalmology and medical aesthetics. Its core offering is an investment fund leveraging a unique information advantage approach. This integrates deep insights from a proprietary Key Opinion Leader network and industry experts for robust evaluation and guidance.
The firm was founded by Managing Partner Jeffry Weinhuff, drawing on his extensive career in private equity and investment banking. The insight: unparalleled access to specialist knowledge yields superior outcomes. This drives Visionary Ventures' strategy of partnering with ophthalmic Key Opinion Leaders for scientific and market validation.
Visionary Ventures serves limited partners by targeting strong returns, and innovative life sciences companies with strategic capital and guidance. The firm seeks entrepreneurial ventures addressing unmet medical needs. Its vision is to foster transformative advancements across global ophthalmology, connecting capital with groundbreaking insights.
Visionary Ventures has 7 tracked investments across 6 companies. The latest tracked deal is $120.0M Series B in Pelage Pharmaceuticals in October 2025.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Oct 1, 2025 | Pelage Pharmaceuticals | $120.0M Series B | ARCH Venture Partners, Cathy Friedman | Main Street Advisors, YK Bioventures |
| Aug 1, 2025 | Iantrek | $42.0M Series C | U.S. Venture Partners | Amoon Fund, Casey Tansey, Civilization Ventures, Radius Special Situations Fund, Sectoral Asset Management |
| Feb 27, 2024 | Pelage Pharmaceuticals | $16.8M Series A | Cathy Friedman | Main Street Advisors, YK Bioventures |
| Apr 1, 2022 | Aurion Biotechnologies | $120.0M Series U | Deerfield Management | Alcon, Falcon Vision, Flying L Partners, Patrick Lally |
| Aug 12, 2020 | TearClear | $22.0M Series B | — | Bluestem Capital, Falcon Vision, Flying L Partners |
| Jan 8, 2020 | Tarsus Pharmaceuticals | $60.0M Series B | Chen YU | Aperture Venture Partners, Flying L Partners, Frazier Healthcare Partners, Horowitz Group |
| Jun 1, 2018 | Orasis Pharmaceuticals | $13.0M Series B | Visionary Ventures | Sequoia Capital Israel, Rafi Gidron |
